Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check4 days agoChange DetectedPage version updated from v3.0.1 to v3.0.2; the 'Back to Top' control was removed. No other core content, pricing, or availability changes were detected.SummaryDifference0.1%
- Check11 days agoChange DetectedThe page has been updated to reflect a new version, v3.0.1, indicating a recent revision. The previous version, v3.0.0, has been removed from the page.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has been updated to include new facility and location information, as well as specific details about differentiated thyroid carcinoma and associated treatments, while removing outdated location and medical topic references.SummaryDifference4%
- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.